Alicapistat is a new drug being developed to treat AD by inhibiting calpain 1/2 activity, and trials were terminated due to inadequate CNS concentrations to obtain a pharmacodynamic effect [9]. This evidence concerns the gene CAPN1 and Alzheimer disease.